Phibro Animal Health is a Teaneck, New Jersey production-animal franchise that spent fiscal 2026 proving it could absorb the medicated-feed-additive book it bought from Zoetis and still print a record year. The equity is no longer debating whether that deal closed. The debate is whether the first full year of the enlarged company is a new earning power or a purchased peak that antimicrobial rules, a fading acquired-product print, and almost no free cash now expose. Class A shares last changed hands at $34.56, which is closer to the fifty-two-week low than to the high near $60. That gap is the market saying the bounce already happened.
The tension sits in the mix, not in the headline. Animal Health still carried the year, but fourth-quarter growth inside that segment slowed to a crawl while the acquired Zoetis lines, which management labels Z-Product, declined. Brazil then changed the rulebook. Ordinance 1617 from the Ministry of Agriculture and Livestock bars growth-promotion use of virginiamycin and bacitracin after a half-year transition, and fiscal 2027 guidance already assumes almost no Brazilian virginiamycin. Cash conversion did not keep up with the income statement. Free cash flow for the year was only $9.9 million after a heavy inventory build and plant spending, against $255 million of adjusted EBITDA. Gross leverage still sits near three times that earnings figure.
What the next year has to show is whether the legacy franchise compounds without another purchased step-up. Sales guidance sits in a band around one and a half billion. Adjusted earnings guidance barely steps up from last year's print. The deceleration is sharp enough that the year looks like a plateau rather than a second act. Dani Bendheim took the chief-executive chair on the first day of fiscal 2027 after Jack Bendheim moved to executive chairman, so the first year of the new office is also the first year the deal has to stand on organic demand, therapeutic labels in Brazil, and a Chicago Heights plant move that the company has not yet costed. The question is simple: is this a sustainably larger livestock-health company, or a family-controlled roll-up whose best year is already in the rear-view mirror?